Novavax' Preclinical Influenza Nanoparticle Study Published in Vaccine
(Thomson Reuters ONE) -
Novel vaccine candidate, NanoFlu(TM), outperforms market-leading Fluzone® High
Dose based on antibody titers and neutralization of recent and historic
influenza viruses in a preclinical study
GAITHERSBURG, Md., Aug. 23, 2017 (GLOBE NEWSWIRE) -- Novavax, Inc.,
(Nasdaq:NVAX) today announced that data from a preclinical study of its
nanoparticle influenza vaccine candidate with its proprietary Matrix-M(TM)
adjuvant (NanoFlu(TM)) have been published in the journal Vaccine. Novavax is
developing NanoFlu to protect older adults from seasonal influenza.
The manuscript describes the formulation of Novavax' novel seasonal influenza
vaccine candidate, NanoFlu, based on the 2017-2018 World Health Organization
(WHO) recommended influenza strains. The study, conducted in ferrets, found that
NanoFlu induced hemagglutination-inhibition (HAI) and microneutralizing (MN)
antibodies against a broad range of influenza subtypes. In a head-to-head
comparison against standard-dose and high-dose (HD) inactivated influenza
vaccines in ferrets, NanoFlu elicited higher HAI and MN antibody responses
exceeding those induced by the high-dose vaccine against recent (homologous)
A(H3N2) by 7-fold, A(H1N1) by 26-fold, and B strain viruses by 2-fold.
Additionally, NanoFlu induced superior protection in a ferret challenge model
against a homologous and a 10-year old drifted influenza strain spanning over a
decade.
"These data suggest that NanoFlu has the potential to elicit a broader, more
robust immune response, resulting in greater protection than the market-leading
licensed influenza vaccine in older adults, Sanofi's Fluzone® High-Dose. NanoFlu
outperformed standard dose Fluzone and Fluzone HD in HAI assays, an established
surrogate marker of protection," said Gregory Glenn, M.D., President, Research
and Development. "Further, these data suggest NanoFlu has the potential to
address the problem of annual strain mismatch due to its ability to induce
highly neutralizing antibodies against a broad range of influenza strains. These
data show that NanoFlu provides improved protective responses to both the
current recommended influenza strains as well as drifted strains."
"Novavax has over a decade of experience in developing both seasonal and
pandemic influenza vaccine candidates. Based on the superior attributes of our
nanoparticle based vaccine candidates, we transitioned our influenza development
activities to our nanoparticle vaccine platform," said Stanley C. Erck,
President and CEO. "The data in this publication further validate our
nanoparticle vaccine platform and provide a strong rationale for advancing
NanoFlu into a Phase 1/2 clinical trial. Our goal is to deliver a superior,
differentiated vaccine to the greater than $3 billion global seasonal influenza
commercial market(1)."
Copies of this paper are available to credentialed journalists upon request;
please contact Elsevier's Newsroom at newsroom(at)elsevier.com or +31 20 485 2492.
"Novel hemagglutinin nanoparticle influenza vaccine with Matrix-M(TM) adjuvant
induces hemagglutination inhibition, neutralizing, and protective responses in
ferrets against homologous and drifted A(H3N2) subtypes," by Gale Smith, Ph.D.,
Ye Liu, Ph.D., David Flyer, Ph.D., Michael J. Massare, Ph.D., Bin Zhou, Ph.D.,
Nita Patel, Ph.D., Larry Ellingsworth, Ph.D., Maggie Lewis, Ph.D., James F.
Cummings, M.D., Greg Glenn, M.D., DOI:
http://dx.doi.org/10.1016/j.vaccine.2017.08.021 appears in Vaccine, published by
Elsevier and is available online at www.elsevier.com/locate/vaccine.
About Vaccine
Vaccine is the pre-eminent journal for those interested in vaccines and
vaccination. It is the official journal of The Edward Jenner Society and The
Japanese Society for Vaccinology and is published by Elsevier,
www.elsevier.com/locate/vaccine.
About Novavax
Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage biotechnology company committed
to delivering novel products to prevent a broad range of infectious diseases.
Our recombinant nanoparticles and Matrix-M(TM) adjuvant technology are the
foundation for groundbreaking innovation that improves global health through
safe and effective vaccines. Additional information about Novavax is available
on the Company's website, novavax.com.
References
1. PharmaPoint Seasonal Influenza Vaccines Global Drug Forecast and Market
Analysis to 2025, October 2016
Forward-Looking Statements
Statements herein relating to the future of Novavax and the ongoing development
of its vaccine and adjuvant products are forward-looking statements. Novavax
cautions that these forward looking statements are subject to numerous risks and
uncertainties, which could cause actual results to differ materially from those
expressed or implied by such statements. These risks and uncertainties include
those identified under the heading "Risk Factors" in the Novavax Annual Report
on Form 10-K for the year ended December 31, 2016 and the Report on Form 10-Q
for the period ended June 30, 2017, both as filed with the Securities and
Exchange Commission (SEC). We caution investors not to place considerable
reliance on the forward-looking statements contained in this press release. You
are encouraged to read our filings with the SEC, available at sec.gov, for a
discussion of these and other risks and uncertainties. The forward-looking
statements in this press release speak only as of the date of this document, and
we undertake no obligation to update or revise any of the statements. Our
business is subject to substantial risks and uncertainties, including those
referenced above. Investors, potential investors, and others should give careful
consideration to these risks and uncertainties.
Contact:
Investor Relations
Novavax, Inc.
Andrea N. Flynn, Ph.D.
Director, Investor Relations
ir(at)novavax.com
240-268-2000
Westwicke Partners
John Woolford
john.woolford(at)westwicke.com
443-213-0506
Media
Russo Partners, LLC
David Schull
Maggie Beller
david.schull(at)russopartnersllc.com
maggie.beller(at)russopartnersllc.com
212-845-4271
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Novavax, Inc. via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Datum: 23.08.2017 - 13:00 Uhr
Sprache: Deutsch
News-ID 557559
Anzahl Zeichen: 7448
contact information:
Town:
Maryland
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 197 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Novavax' Preclinical Influenza Nanoparticle Study Published in Vaccine"
steht unter der journalistisch-redaktionellen Verantwortung von
Novavax, Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
